Aesica Pharmaceuticals Receives Majority Investment from Silverfleet Capital

Aesica Pharmaceuticals, a UK-based pharmaceutical company, has received a majority investment from Silverfleet Capital. Aesica executives have reinvested for a large minority stake in the company. The investment will help Aesica continue to grow and expand into new markets. Silverfleet Capital will replace LDC's majority shareholding in the business.  David Mackenzie and Adrian Yurkwich from Silverfleet Capital will join the company's board as non-executive directors.

Aesica Pharmaceuticals Secures Majority Investment from Silverfleet Capital

Aesica Pharmaceuticals is a Cramlington, UK-based company that develops and manufactures primary (API) and secondary stage (finished product dosage forms) pharmaceuticals.  It operates six manufacturing sites across Europe and has sales representation across the US, Europe and Asia. It intends to extend its capabilities and global manufacturing facilities.

A UK-based company that develops and manufactures primary (API) and secondary stage (finished product dosage forms) pharmaceuticals.

14 years ago

Aesica Pharmaceuticals Secures Majority Investment from Silverfleet Capital

Covered on